Evidence map›Paper›PMID 42385125›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026

Efficacy and Tolerability of Zenocutuzumab in Advanced

James M Cleary, Christoph Springfeld, Dirk Arnold, Antoine Hollebecque, Olumide Gbolahan, Misako Nagasaka, Salvatore Siena, Frans Opdam, Yu Sunakawa, Philippe A Cassier and 10 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

James M ClearyDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-7213-3951
Christoph SpringfeldHeidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0003-3843-101X
Dirk ArnoldAsklepios Klinik Altona, Hamburg, Germany.ORCID 0000-0003-2392-599X
Antoine HollebecqueGustave Roussy, Villejuif, France.ORCID 0000-0003-2869-7551
Olumide GbolahanEmory Winship Cancer Institute, Atlanta, GA.
Misako NagasakaUniversity of California Irvine School of Medicine, Orange, CA.ORCID 0000-0001-5308-615X
Salvatore SienaDepartment of Hematology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.ORCID 0000-0002-2681-2846
Frans OpdamNetherlands Cancer Institute, Amsterdam, the Netherlands.
Yu SunakawaSt Marianna University Hospital, Kawasaki, Japan.ORCID 0000-0002-0163-7543
Philippe A CassierCentre Léon Bérard, Lyon, France.ORCID 0000-0003-3857-1688
Gaurav TrikhaCancer Specialists of North Florida, Jacksonville, FL.
Eelke H GortUniversitair Medisch Centrum Utrecht, Utrecht, the Netherlands.ORCID 0000-0001-7390-0761
Vaia FlorouHuntsman Cancer Institute, Salt Lake City, UT.ORCID 0000-0001-5558-753X
Richard GreilSalzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, Salzburg, Austria.
Paul F La PorteThe Oncology Institute of Hope and Innovation-Long Beach, Cerritos, CA.
Pritesh J GandhiPartner Therapeutics, Inc, Lexington, MA.
Fiona GarnerPartner Therapeutics, Inc, Lexington, MA.ORCID 0000-0002-5969-2561
Ernesto WassermanMerus, Cambridge, MA.
Shola AdeyemiMerus, Cambridge, MA.
Alison M SchramMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-6070-2413

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePresently, to our knowledge, there are no approved targeted therapies for neuregulin 1 gene fusion-positive (

methodseNRGy is a single-arm, phase II study of zenocutuzumab in advanced

resultsAs of July 31, 2025, 22 patients (median age 57.5 years) with advanced

conclusionZenocutuzumab demonstrated clinically meaningful and durable antitumor activity with a favorable safety profile in patients with advanced

Indexed as

Antineoplastic Agents, ImmunologicalBile Duct NeoplasmsCholangiocarcinomaNeuregulin-1Oncogene Proteins, FusionAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedProgression-Free SurvivalAntineoplastic Agents, ImmunologicalNeuregulin-1NRG1 protein, humanOncogene Proteins, Fusion

Identifiers

PMID42385125
PMCPMC13682725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.